Youngene Therapeutics Inc., Ltd.   Report issue

For profit Phase 2
Founded: Shanghai China (2016)

Organization Overview

First Clinical Trial
2019
NCT03953092
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Youngene Therapeutics Inc., Ltd.